Loading...

ADC Therapeutics SA (NYSE:ADCT)

8.02 USD +0.13 USD ( +1.65% )
Watchlist Manager
ADC Therapeutics SA
NYSE:ADCT
Watchlist

P/S
Price to Sales

The Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.

P/S
=
Market Cap
/
Revenue
Current P/S
ADCT
7.7
Median P/S
ADCT
N/A
Industry P/S
Biotechnology
10

P/S History

Statistics
Price to Sales

1 Year 3 Years 5 Years
Average 156.9 55.1 33.4
Median 45.7 N/A N/A
Min N/A N/A N/A
Max 598.3 598.3 598.3

History Chart
Price to Sales

P/S Forward Multiples

Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/S
4.8
2-Years Forward
P/S
3.8
3-Years Forward
P/S
2.1

P/S Across Competitors

ADCT Competitors
ADC Therapeutics SA Competitors

Country Company Market Cap P/S
CH
ADC Therapeutics SA
NYSE:ADCT
616M USD 7.7
US
Abbvie Inc
NYSE:ABBV
271B USD 4.8
US
Amgen Inc
NASDAQ:AMGN
131B USD 5
AU
CSL Ltd
ASX:CSL
131B AUD 8.5
US
Gilead Sciences Inc
NASDAQ:GILD
78.9B USD 2.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
73.4B USD 9.2

Relative Valuation Report

View full relative valuation report for ADC Therapeutics SA, which takes into account all ADCT`s valuation multiples.

See Also

Similar Stocks